The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105
Abstract
Purpose: This phase III trial of concurrent thoracic radiotherapy (TRT) was conducted to compare third-generation chemotherapy with second-generation chemotherapy in patients with unresectable stage III non–small-cell lung cancer (NSCLC). Patients and Methods: Eligible patients received the following treatments: A (control), four cycles of mitomycin (8 mg/m 2 on day 1)/vindesine (3 mg/m 2 on days 1, 8)/cisplatin (80 mg/m 2 on day 1) plus TRT 60 Gy (treatment break for 1 week); B, weekly irinotecan (20 mg/m 2)/carboplatin (area under the plasma concentration-time curve [AUC] 2) for 6 weeks plus TRT 60 Gy, followed by two courses of irinotecan (50 mg/m 2 on days1, 8)/carboplatin (AUC 5 on day1); C, weekly paclitaxel (40 mg/m 2)/carboplatin (AUC 2) for 6 weeks plus TRT 60 Gy, followed by two courses of paclitaxel (200 mg/m 2 on day1)/carboplatin (AUC 5 on day 1). Results: The median survival time and 5-year survival rates were 20.5, 19.8, and 22.0 months and 17.5%, 17.8%, and 19.8% in arms A, B, and C, respectively. Although no significant differences in overall survival were apparent among the treatment arms, noninferiority of the experimental arms was not achieved. The incidences of grade 3 to 4 neutropenia, febrile neutropenia, and gastrointestinal disorder were significantly higher in arm A than in arm B or C (P < .001). Chemotherapy interruptions were more common in arm B than in arm A or C. Conclusion: Arm C was equally efficacious and exhibited a more favorable toxicity profile among three arms. Arm C should be considered a standard regimen in the management of locally advanced unresectable NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Furuse, K., Fukuoka, M., Kawahara, M., Nishikawa, H., Takada, Y., Kudoh, S., Katagami, N., & Ariyoshi, Y. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2692 · Cited by 1,495
Self-citationDillman, R. O., Seagren, S. L., Propert, K. J., Guerra, J., Eaton, W. L., Perry, M. C., Carey, R. W., Frei, E. F., & Green, M. R. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231403 · Cited by 1,153
Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer
Sause, W., Kolesar, P., Taylor, S., Johnson, D., Livingston, R., Komaki, R., Emami, B., Curran, W., Byhardt, R., Dar, A. R., et al. (2000) · Chest · doi:10.1378/chest.117.2.358 · Cited by 627
Hoffman, P. C., Mauer, A. M., & Vokes, E. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)82038-3 · Cited by 605
Hanna, N., Neubauer, M., Yiannoutsos, C., McGarry, R., Arseneau, J., Ansari, R., Reynolds, C., Govindan, R., Melnyk, A., Fisher, W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7840 · Cited by 491
Vokes, E. E., Herndon, J. E., Kelley, M. J., Cicchetti, M. G., Ramnath, N., Neill, H., Atkins, J. N., Watson, D. M., Akerley, W., & Green, M. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3569 · Cited by 478
Belani, C. P., Choy, H., Bonomi, P., Scott, C., Travis, P., Haluschak, J., & Curran, W. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.55.405 · Cited by 424
Cited by
Palma, D. A., Senan, S., Tsujino, K., Barriger, R. B., Rengan, R., Moreno, M., Bradley, J. D., Kim, T. H., Ramella, S., Marks, L. B., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.04.043 · Cited by 674
Self-citation
Metadata
- Authors
- Yamamoto, N., Nakagawa, K., Nishimura, Y., Tsujino, K., Satouchi, M., Kudo, S., Hida, T., Kawahara, M., Takeda, K., Katakami, N., Sawa, T., Yokota, S., Seto, T., Imamura, F., Saka, H., Iwamoto, Y., Semba, H., Chiba, Y., Uejima, H., & Fukuoka, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-08-10
- Volume
- 28
- Issue
- 23
- Pages
- 3739-3745
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2160797118
- Cited by
- 301
- References
- 13
- FWCI
- 15.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105. https://app.cochat.ai/papers/10.1200/jco.2009.24.5050
- The paper
- Yamamoto, N., Nakagawa, K., Nishimura, Y., Tsujino, K., Satouchi, M., Kudo, S., Hida, T., Kawahara, M., Takeda, K., Katakami, N., Sawa, T., Yokota, S., Seto, T., Imamura, F., Saka, H., Iwamoto, Y., Semba, H., Chiba, Y., Uejima, H., & Fukuoka, M. (2010). Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.24.5050
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.